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Abstract
A comparative study of public gene-expression data of seven types of cancers (breast, colon, kidney, lung, pancreatic,
prostate and stomach cancers) was conducted with the aim of deriving marker genes, along with associated pathways, that
are either common to multiple types of cancers or specific to individual cancers. The analysis results indicate that (a) each of
the seven cancer types can be distinguished from its corresponding control tissue based on the expression patterns of a
small number of genes, e.g., 2, 3 or 4; (b) the expression patterns of some genes can distinguish multiple cancer types from
their corresponding control tissues, potentially serving as general markers for all or some groups of cancers; (c) the proteins
encoded by some of these genes are predicted to be blood secretory, thus providing potential cancer markers in blood; (d)
the numbers of differentially expressed genes across different cancer types in comparison with their control tissues correlate
well with the five-year survival rates associated with the individual cancers; and (e) some metabolic and signaling pathways
are abnormally activated or deactivated across all cancer types, while other pathways are more specific to certain cancers or
groups of cancers. The novel findings of this study offer considerable insight into these seven cancer types and have the
potential to provide exciting new directions for diagnostic and therapeutic development.
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Introduction
Cancer is a key threat to people’s health and life, accounting for
,13% of all disease-causing deaths in the world [1]. In 2007, 7.6
million people died of cancer world-wide. In the U.S, over 1.4
million new cancer cases were reported each year in the past few
years, and cancer becomes the second leading cause of death
following heart disease. Statistics from the SEER reports indicate
that the mortality rate across all cancer types in the U.S. went
from 195.4 per 100,000 cases in 1950, continued an upward trend
till 1978 reaching 204.4, and then steadily decreased to 184.0 in
2005 [2]. This decreasing trend has been mostly due to the
improved diagnostic techniques for detecting the early stage of
cancer. General survival statistics of cancer indicate that early
detection and treatment are the key to longer survival across all
cancer types.
Challenges in early cancer detection arise mainly from the
reality that most patients are asymptomatic in the early stages of
cancer, and only a few effective cancer-screening tests are clinically
available. While some tests have proved to be effective in detecting
cancer at its early stage, they are often too invasive, such as
colonoscopy, to be routinely used during regular physicals and are
currently limited to only a small number of cancer types. Often a
cancer is already in an advanced stage when diagnosed; clearly,
more effective techniques for early cancer detection are needed.
A number of genetic markers have been proposed for various
cancers, such as BRCA1 and BRCA2 for breast cancer and
CDH1 for gastric cancer. In addition, a number of promising
serum markers for cancer have been used clinically. Among them,
PSA (prostate-specific antigen) is the most well known and has
been widely used for diagnosing prostate cancer through blood
tests [3]. However, its effectiveness of detection is far from
adequate, widely considered as having a false positive rate that is
too high to be a reliable cancer-indicator [4]. Similar observations
have been made about other serum markers such as CA125 for
ovarian cancer [5].
Herein we present a computational study on prediction of both
genetic and serum markers for seven cancer types, based on public
microarray gene-expression data and a computer program for
prediction of blood-secretory proteins [6]. Compared to earlier
studies on cancer marker identification, including meta-analyses
on multi-types of cancers [7], the present study has the following
unique features: (i) a focus on identification of multi-gene markers
through exhaustive analysis of all possible combinations of genes,
taking full advantage of the available high-level computing power,
rather than using heuristic approaches that may not necessarily
find the optimal markers; (ii) an attempt to find markers for groups
of cancers in addition to those for individual cancers; (iii) an
attempt to link the information derived from transcriptomic data
of tissues to marker prediction in serum using the novel prediction
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abnormally regulated, either common across multiple cancer
types or specific to individual cancer types. We believe that these
novel data will prove highly valuable in elucidating the genetic
alterations in various cancers, as well as offering potential
directions for new approaches in diagnostics and therapeutics.
Materials and Methods
1. Microarray gene expression data for human cancers
Microarray gene expression data were downloaded for seven
cancer types, namely, breast, colon, kidney, lung, pancreatic,
prostate and stomach cancer from the GEO database of NCBI [8].
To ensure that our prediction results can be generalized to
different datasets, two independent test sets were used to evaluate
the robustness of the predicted gene markers obtained from the
training set. Detailed information of the data is listed in Table S1.
In this study, we have chosen the largest available microarray
datasets from each of the seven cancer types, where each dataset
includes the (normalized) gene expression levels of each gene in
both cancer and control tissues of each patient, along with the
stage information for the majority of the cancer samples (some
data does not have this information). Note that all the microarray
datasets used are normalized using RMA, which has been
reported to be more accurately reflective of biological changes
compared to other methods like MAS5 (Affymetrix). The
distributions of the fold-changes (FC) of individual genes across
all genes between cancer and the corresponding control tissues for
the seven types of cancers were checked and found to be highly
similar. Figure S1 shows one such comparison of FC distributions
between breast cancer and lung cancer; hence we believe that
comparisons of fold-changes across different cancer datasets in our
study are meaningful.
2. Identification of differentially expressed genes
For datasets with unpaired cancer and control samples from the
same patients, Mann-Whitney test was applied to identify genes
that are differentially expressed in cancer versus control samples.
For those datasets with paired information the test is as follows:
Given the hypothesis H0 that a particular gene is not differentially
expressed in cancer versus the control group, the rejection of this
hypothesis means that the gene is differentially expressed in
cancer. Let N½i  and C½i , be the gene’s expression levels in control
and cancer tissues of i-th patient, i=1… m, and m be the number
of patients. It is obvious that if the hypothesis H0 is true, then the
probability P(N½i wC½i )=P(N½i vC½i )=0.5, assuming the
gene’s expression is a continuous random variable. Let K be the
number of patients with N½i =C½i w0:5, then the random variable
K/m approximately follows a normal distribution (according to the
Central Limit Theorem or de Moivre-Laplace Theorem) with its
mean=0.5 and a standard variation=:5=
ﬃﬃﬃﬃ
m
p
,o rX~2K=
ﬃﬃﬃﬃ
m
p
follows a normal distribution N(0,1). Thus the p-value can be
estimated as P(X.2Kexp=
ﬃﬃﬃﬃ
m
p
), where Kexp is the number of
patients satisfying P(N½i vC½i ). Overall, we consider a gene
being differentially expressed if the statistic significance, p-value, is
less than 0.05 and its fold-change is at least 2.
3. Prediction of blood secreted proteins
All genes predicted to be differentially expressed between cancer
and the corresponding control samples were analyzed to predict if
their proteins are blood-secretory, using a program that our group
recently developed [6]. The basic idea of the algorithm is to train a
support vector machine (SVM)-based classifier to distinguish
between the blood-secretory proteins and proteins that are not
secreted, using various sequence-based features such as signal
peptides, transmembrane domains, glycosylation sites and polarity
measures. On a large independent test set containing 105 secretory
proteins and 7,258 non-secretory proteins of humans, the classifier
achieved ,94% prediction sensitivity and ,98% prediction
specificity.
4. Prediction of marker genes for each cancer type
For each k-gene combination out of the differentially expressed
genes defined in the above section, an SVM-based classifier was
trained to achieve the highest possible classification accuracy
defined as
Overall accuracy~ TPzTN ðÞ =N,
where TP and NP are the numbers of true positives and negatives,
respectively, and N is the total number of samples. A linear kernel
function was used for training through LIBSVM [9]. For each
cancer type, all markers were ranked according to the 5-fold cross-
validation performance on the training dataset. In order to find
markers that are generalized well to other datasets, we tested the
predicted gene markers on two independent test datasets.
5. Prediction of markers for multiple cancer types
To identify k-gene discriminators for multiple cancer types, all
genes that consistently exhibit differential expressions in at least
two cancer types were considered. For each k-gene combination
among these genes, its classification accuracy between each cancer
type and the corresponding control tissues was calculated. Then,
the k-gene combinations exhibiting discerning power across
multiple cancer types were determined. The top discriminators
for multi-cancer types were selected by using a fixed cut-off on
classification accuracies. Throughout the remainder of this paper,
k-gene groups refer to combinations of k-genes for k=1, 2, 3, 4
unless stated otherwise.
6. Pathway enrichment analysis of differentially
expressed genes
Functional analysis and pathway enrichment analysis were
conducted using DAVID [10], where the pathway information is
based on the annotation from KEGG, BBID and BIOCARTA. A
p-value,0.05 was used to guarantee the significance level of an
enriched pathway.
Results
This study is focused on seven of the most prevalent cancer
types in the world, which also have large sets of microarray gene-
expression data available in the public domain, collected at a
genome scale from tissues of each cancer type as well as from their
corresponding noncancerous control tissues. By working on
multiple cancer types simultaneously, we can derive potential
markers either specific to individual cancer types or general to all
or groups of cancers, as well as to identify abnormally activated or
deactivated pathways.
1. Predicted marker genes for individual cancer types
We have searched for individual genes and gene combinations
whose expression patterns can best distinguish between cancer and
associated control tissues for each cancer types. Specifically, all 1-,
2-, 3- and 4-gene combinations encoded in the human genome
were ranked in terms of their discerning power in distinguishing
the cancer samples from the corresponding control samples for
Compar Analysis of MultiCancer
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combinations, based on their discerning power between early
cancer samples and control samples if the relevant data are
available and sufficiently large.
A. Breast cancer. The analysis was done on a gene-
expression dataset consisting of 43 paired breast cancer and
cancer-adjacent control tissues from the same patients [11]. Of the
43 samples, 32 were early-stage cancers (stages I and II). 294 genes
were found to be consistently and abnormally expressed with at
least a 2-fold change in their expression across the cancer and the
control tissues, 81 of which were up-regulated and 213 were down-
regulated in the cancer tissues. Among the differentially expressed
genes, 69 of their encoded proteins are predicted to be blood
secretory by our prediction program [6], and could thus serve as
potential serum biomarkers (Supplementary Information File S1).
Classification analysis was then conducted (see Materials and
Methods), with the goal of identifying k-gene combinations whose
expression patterns can accurately distinguish between the cancer
and the control samples. Figure 1 (A) and (D) show the
classification accuracies of the best 100 k-gene combinations on
the whole training set and on the training set containing only early
stage samples, respectively. Two independent evaluation sets are
used to assess the generality of the identified gene markers, which
consist of 31 and 68 breast cancer, and 27 and 61 control samples
[12], respectively. Figure 1 (B) and (C) show the classification
performance by the trained classifiers on the two evaluation sets.
The detailed list of these 100 k-gene combinations is given in
Suppplementary Information S1.
As shown in Figure 1, the majority of the top k-gene
combinations, particularly for k.1, perform well on both training
Figure 1. Classification accuracies by the top 100 k-gene markers, k=1, 2, 3, 4, on the training and the test sets of breast cancer. For
each panel, the x-axis is the list of 100 k-gene markers ordered by their classification performance on the training datasets, and the y-axis represents
the classification accuracy. (A) classification accuracies by the top 100 k-gene combinations between breast cancer and reference samples in the
training set, and (B) and (C) on the two test sets; (D) classification accuracies by top 100 k-gene combinations between early breast cancer and
corresponding reference samples in the training set and (E) on the test set.
doi:10.1371/journal.pone.0013696.g001
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85% although their ranking orders on the two datasets may not be
well preserved. The fluctuations in their classification accuracies
are believed to be due to the small size of the training data. Similar
observations were made on all the predicted top markers across
the seven cancer types.
The best three single gene discriminators are PCOLCE2,
ANGPTL4 and LEP, having 88.4%, 88.4% and 87.2% classifi-
cation accuracy on the training set and 94.8% and 84.1%, 84.5%
and 79. 5% and 96.6% and 96.1% on the two test sets,
respectively. The top three 2-, 3- and 4-gene combinations are
{TACSTD2+CHRDL1, TACSTD2+CAV1, PPARG+TMEM97},
{RRM2+COL1A1+PPARG, RRM2+COL1A1+PCOLCE2, RRM2
+GPR109B+SPINT2}, and {RRM2+COL1A1+GPR109B+SPINT2,
RRM2+GPR109B+INHBA+SPINT2, TACSTD2+IGFBP6+IGF1
+TF}, respectively. Similarly, for early breast cancer, the best three k-
gene discriminators are {GPR109B, PCOLCE2, PCSK5}, {PCSK5+
COL10A1, FERMT2+SPINT2, MAOA+IGJ}, {COL1A1+
PCSK5+TF, GPX3+COL1A1+SPINT2, GPX3+FAP+TMEM97},
and {RRM2+COL1A1+GPR109B+IGJ, RRM2+COL1A1+GPR
109B+IGJ, RRM2+COL1A1+GPR109B+SPINT2}, respectively.
Although the best three discriminators represent novel discov-
eries, we noticed some lower-ranked genes have been considered
as possible breast cancer markers by previous studies. For
example, ADIPOQ (adiponectin) is found to be closely associated
with a breast-cancer risk [13]. The SPINT2, an inhibitor of HGF
activator, was reported to have higher expression levels in early
stage breast cancer and associated with a poor prognosis [14],
consistent with our findings. Some others are involved in the
activities of cancer cells in general. For example, CAV1, down-
regulated in the cancer samples, was found to inhibit breast cancer
growth and metastasis [15]; the down-regulation of PPARG is
associated with local recurrence and metastasis in breast cancer
[16]; and ANGPTL4 may act as a regulator of angiogenesis [17].
To the best our knowledge, all the 2-, 3- and 4-gene discriminators
represent novel discoveries.
Similar analyses have been carried out on six other cancer types.
The key findings on each of these six cancer types are highlighted
below, with the summary being given in Table S2 and gene names
listed in Supplementary Information File S1. In addition,
Supplementary Information File S2 show the classification
accuracies by the best 100 k-gene discriminators on both the
training and the testing sets for each cancer type, respectively.
B. Colon cancer. Our analysis was done on a microarray
dataset consisting of 53 colon cancer and 28 cancer-adjacent
control tissues from the same patients (some of the cancer samples
have no reference samples) [18]. 247 genes were found to be
consistently and abnormally expressed with at least a 2-fold change
in their expression across the cancer and the control tissues in our
training data, 56 of which are up-regulated and 191 are down-
regulated in colon cancer tissues. Two independent test sets,
consisting of 24 and 22 colon cancer and 24 and 20 cancer-
adjacent control samples from the same patients [19], respectively,
were used to assess the generality of the predicted markers.
We found the best three single-gene discriminators for colon
cancer are MMP7, DPT and MMP1 having 97.5%, 96.3% and
95.1% classification accuracy on the training set, and 97.9% and
90.9%, 97.9% and 74.6%, and 91.7% and 84.1% on the two test
sets, respectively. The top three 2-gene discriminators are
SLIT3+MMP7, MATN2+MMP7, and MMP7+PTGS1. Some
of our top discriminators have been previously studied in the
context of colorectal cancer. For example, MMP1 is an invasion-
promoting factor, and its up-regulation, as observed in our data, is
associated with the invasiveness of the cancer [20]. MMP7 is
known to play an important role in cancer growth, and its up-
regulation could be a key mechanism for cancer cells’ escape from
the immune surveillance [21].
C. Kidney cancer. The analysis was carried on a microarray
gene-expression dataset consisting of 49 kidney cancer and 23
cancer-adjacent control tissue samples from the same patients
[22]. 231 genes were found to be consistently and abnormally
expressed with at least a 2-fold change in their expression across
the cancer and control tissues in our training data, 129 of which
are up-regulated and 102 are down-regulated in cancer. Two
independent evaluation sets, consisting of 35 and 36 kidney cancer
samples and 12 and 9 cancer-adjacent control samples from the
same patients, respectively, were used to assess the generality of the
predicted markers [23,24]. The best three single gene
discriminators are found to be UMOD, ACPP and CCL18 for
kidney cancer, having the same classification accuracy, 98.6% on
the training set and 100% and 94.4%, 95.7% and 86.11% and
89.4% and 68.1% on the two test sets, respectively. The top three
2-gene combinations are EGF+ALB, ACPP+UMOD, and
UMOD+ALB. Among the top discriminators, UMOD has been
reported to be related to kidney disease [25]. SERPINA5, down-
regulated in the cancer, regulates the invasive potential of renal
cancer growth and invasion. Other top discriminators represent
new discoveries. For example, AFM has not been reported to be
related to cancer, and C6orf155 does not have a characterized
function.
D. Lung cancer. The analysis was done on a microarray
dataset consisting of 58 lung cancer tissue and 49 cancer-adjacent
control tissue samples from the same patients [26]. 683 genes were
found to be consistently and abnormally expressed with at least a
2-fold change in their expression across the cancer and control
tissues in our training data, 255 of which are up-regulated and 428
are down-regulated in lung cancer tissues. Two independent sets,
consisting of 27 and 20 lung cancer and 27 and 19 cancer-adjacent
control samples from the same patients [27], was used to assess the
generality of the predicted markers.
The best three single gene discriminators are CAV1, SFTPC
and VWF for lung cancer, having the same classification accuracy,
99.1% on the training set and 98.2% and 100%, 96.3% and
82.5%, and 88.9% and 100% on the two test sets, respectively.
The top three 2-gene combinations are FERMT2+GREM1,
TEK+NFASC, CAV1+MMP1. Among the top discriminators,
CAV1 has been found to be down-regulated in breast cancer [28],
and has been reported to be associated with metastasis in lung
cancer [29]. SFTPC has been reported to be associated with
interstitial lung disease [30]. FAM107A, which suppresses cell
growth, may play a role in cancer development [31]. Other top
discriminators represent new observations. For examples, TNXB,
SPP1 and EMCN have not previously been reported as cancer-
related.
E. Pancreatic cancer. The analysis was done on a
microarray dataset consisting of 39 paired pancreatic cancer and
cancer-adjacent control tissue samples from the same patients
[32]. 885 genes were found to be consistently and abnormally
expressed with at least a 2-fold change in their expression across
the cancer and control tissues in the training data, 616 of which
are up-regulated and 269 are down-regulated in pancreatic
cancer. Two independent sets, consisting of 36 and 29
pancreatic cancer samples and 16 and 5 cancer-adjacent control
samples from the same patients [33], was used to assess the
generality of the predicted markers.
The best three single-gene discriminators are KRT17, CO-
L10A1 and CTHRC1 for pancreatic cancer, having the same
classification accuracy, 93.6% on the training set and 88.5% and
Compar Analysis of MultiCancer
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e1369680.4%, 84.6% and 73.2%, and 84.6% and 85.7% on the two test
sets, respectively. The top three 2- and 3-gene discriminators are
{MMP7+AZGP1; MMP7+FGL1; MMP7+PLA2G1B} and
{CTHRC1+SGPP2+CCL18; TNFRSF21+EGFL6+CTHRC1;
COL10A1+S100A6+RSAD2}, respectively. Among the top
discriminators, KRT17 is known to be involved in tissue repair
[34]. AZGP1 has been reported to cause extensive loss of fat, often
associated with advanced cancers [35]. Other top discriminators
represent new findings. For examples, RSAD2, involved in
antiviral defense, has not been reported as being related to cancer,
as well as SGPP2, known to be involved in pro-inflammatory
signaling [36], and CST4.
F. Prostate cancer. The analysis was done on a microarray
dataset consisting of 65 prostate cancer and 63 cancer-adjacent
control tissue samples from the same patients [37]. 118 genes were
found to be consistently and abnormally expressed with at least a
2-fold change in their expression across the cancer and control
tissues in our training data, of which 23 are up-regulated and 95
are down-regulated in lung cancer tissues. Two independent sets,
consisting of 62 and 53 prostate cancer samples and 47 and 14
cancer-adjacent control samples from the same patients [38], was
used to assess the generality of the predicted markers.
The best three single gene discriminators are MYLK, PALLD
and CAV1 for prostate cancer, having 73.4%, 71.9% and
71.1% classification accuracy on the training set and 83.5% and
62.3%, 69.6% and 72.6%, and 94.2% and 75.5% on the two test
sets, respectively. The top three 2- and 3-gene discriminators
are {LTF+IGF1; LTF+SPARCL1; SMTN+CCK}, {SMTN+
CCK+CCL2; SMTN+CCK+COMP; SMTN+CCK+PLA2G7},
respectively. Among the top discriminators, LTF is known to
inhibit the growth of tumors [39]. IGF1, a growth factor, plays a
role in the development of prostate cancer [40] and has been
reported as an indicator of advanced prostate cancer [41]. Other
top discriminators represent new discoveries. For example,
CHRDL1 may play a role in regulating angiogenesis [42] but
has not been reported to be related to cancer. The same is with
SMTN.
G. Stomach cancer. The analysis was done on a microarray
dataset consisting of 89 stomach cancer and 23 cancer-adjacent
control tissues from the same patients [43]. Out of the 89 cancer
tissue samples, 31 are early-stage cancers. 311 genes were found to
be consistently and abnormally expressed with at least a 2-fold
change in their expression across the cancer and control tissues in
our training data, 166 of which are up-regulated and 145 are
down-regulated in lung cancer tissues. Two independent sets,
consisting of 38 and 16 stomach cancer samples and 31 and 13
cancer-adjacent control samples from the same patients [44,45]
was used to assess the generality of the predicted markers, of which
12 are early stage samples partially paired with 10 control samples.
The best three single-gene discriminators are SERPINH1, BGN
and COL12A1 for stomach cancer, having 99.1%, 98.2% and
98.2% classification accuracy on the training set and 94.2% and
96.7%, 88.4% and 93.3%, and 84.1% and 75.8% on the two test
sets, respectively. The top three 2-gene combinations are
CHGA+SERPINH1, TGFBI+CHGA and PGC+SERPINH1,
respectively. For early stomach cancer, the best three 1-gene
discriminators are also SERPINH1, BGN and COL12A1,
respectively. Among the top discriminators, BGN is known to
have a role in controlling cell growth in cancer [46]. The
abnormal expression of CTHRC1, a regulator of matrix
deposition, has been widely found across different solid cancers
and is considered to be associated with cancer invasion and
metastasis [34]. Of particular interest is that PGC has been
proposed as an indicator of gastric cancer [47], and the serum
level of PGC was used as a biomarker for precancerous lesions of
the stomach [48]. Other top discriminators represent new
discoveries. For example, ABCA5, ADAMTS12 and CLEC3B
have not been reported to be cancer related.
Interestingly, the number of differentially expressed genes across
different cancer types has a wide spread, ranging from 118
(prostate), 231 (kidney), 247 (colon), 294 (breast), 311 (stomach) to
683 (lung) and 885 (pancreatic). One possible explanation is that
these numbers may reflect the aggressiveness of the corresponding
cancers. We did notice that there is strong correlation between the
number of differentially expressed genes in a given cancer type and
thefive-yearsurvivalrateofpatientswiththatcancer[49] (Figure2).
The detailed statistics is given in Table S3. Another interesting
observation is that, while the majority of the differentially expressed
genes with at least a 2-fold change in five cancer types (breast, colon,
lung, prostate, stomach) are down-regulated, in kidney and
pancreatic cancers, the majority of such genes are up-regulated,
possibly suggesting unique characteristics of these two cancer types.
2. Markers for multiple cancer types
We have also sought to identify genes that could be used as
indicators for cancer in general or for a group of cancers. It is
possible to find common gene ‘‘markers’’ across different cancer
types because of the observation that the majority of the cancers, if
not all, undergo a common set of alterations [50] during
oncogenesis, such as self-sufficiency in growth signals, insensitivity
to antigrowth signals, evasion of apoptosis, and tissue invasion and
metastasis. Some of these biological processes may be executed by
the same groups of proteins during the formation and progression
of different cancers, hence possibly giving rise to common markers
for different cancer types.
A. Identification of genes differentially expressed across
multiple cancer types. We have examined differentially
expressed genes with at least 2-fold changes between cancer and
corresponding control tissues across all seven cancer types and
attempted to find those genes common to multiple cancer types.
The key findings are summarized in Table 1.
85 genes are found to be differentially expressed across at least
three cancer types (Table S4), among which 19 genes are across at
least four cancer types, and five genes (ABCA8, DPT, FHL,CDC2
and TOP2A) across five cancer types. The differences in the gene
expression across different cancer types may indicate either a
general or specific relevance of the gene to the corresponding
Figure 2. Correlation between 5-year survival rate and the
number of differentially genes in each cancer type.
doi:10.1371/journal.pone.0013696.g002
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analysis and an extensive literature search. The detailed molecular
function of these genes is summarized in Table S4. 63 out of the 85
genes have been reported to be cancer associated by previous
studies. For example, CDC2, up-regulated in five of the seven
cancers studied, has been reported to be related to colon, prostate
and stomach cancer, which is not surprising in view of its role in
regulating the cell cycle, e.g. entry from G1 to S; TOP2A, again
up-regulated in five of the seven cancers, has been reported to be
associated with gastric [51], breast [52] and ovarian cancer [53],
consistent with its function in DNA strand regulation; Both of
these two genes have been considered as multi-type cancer
markers by a previous meta-analysis of cancer microarray data [7].
RRM2, up-regulated in four of the seven cancers, has been
suggested to be related to esophageal and gastric cancers and
prostate cancer, consistent with its critical role in DNA synthesis
which must be maintained in rapidly dividing cells. In addition, 49
genes have been reported to be relevant to immune diseases, such
as CXCL12, COL1A1, MMP9, and CD36 [54,55,56,57], likely
reflecting an inflammatory–type response often associated with
cancer. Among them, MMP9, important in extracellular matrix
degradation, is up-regulated in three of the seven cancers, and
CD36, which may function in cell adhesion, is down-regulated in
three of the seven cancers; both of these changes are consistent
with a role of the gene products in metastasis.
B. Pathway enrichment analysis of differentially
expressed genes. We have carried out a pathway enrichment
analysis on genes that are differentially expressed in any of the
seven cancer types. Overall, a number of signaling pathways are
consistently and highly enriched across all seven types of cancers,
such as Wnt, p53 and integrin signaling pathways, as well as a few
other processes like phospho-APC/C-mediated degradation of
cyclin A and inflammation determined by chemokine and cytokine
signaling pathways (in addition to the general cellular processes
such as cell cycle, DNA replication and repair, apoptosis and
various metabolic pathways). Notably, these pathways are mostly
enriched with up-regulated genes in cancer, suggesting a possible
activation of these processes. In addition, a few metabolic
pathways such as tyrosine, histidine, phenylalanine, butanoate
and 5-hydroxytryptamine pathways are enriched only with down-
regulated genes across all cancers. This may indicate a possible
deficiency of the relevant metabolic enzymes in cancer, which
could, for example, arise from loss-of-function mutations in their
genes. These observations may suggest the essential roles played by
these processes in cancer formation and progression.
Other than the above processes common to all cancers, a few
pathways are enriched only in specific cancers. For example,
arginine, proline, glutamate and riboflavin (vitamin B2) metabo-
lisms are enriched with up-regulated genes only in lung cancer;
folate biosynthesis and nitrogen metabolism pathways are
Table 1. A list of 19 genes that are differentially expressed in more than 4 cancer types and their relevance to different cancer
types.
Gene ID Direction of regulation Reported to be related to cancers
Breast Colon Kidney Lung Pancreas Prostate Stomach B. C. K. L. Pa. Pr. S. Other cancer types
CDC2 qq q q q * *** * liver cancer; squamous cell
carcinoma;nasopharyngeal carcinoma
AURKA qq q q q ** ****ovarian cancer;esophageal squamous
cancer;uterine cancer;bladder cancer
ABCA8 QQQQ Q
DPT QQ Q Q Q
TOP2A qq q q q ** *bladder cancer;ovarian cancer;
squamous cell carcinoma
MMP7 qq q q ** ** *ovarian cancer; oral cancer; rectal
cancers; bladder cancer; liver cancer
MAD2L1 qq q q ** thyroid carcinomas; oesophageal
squamous cancer
KLF4 QQ Q Q ** *esophageal cancer;bladder cancer
MELK qq q q * brain cancer;endometrial cancer
C7 QQQ Q ** uterine cervical cancers
ECT2 qq q q *
PRC1 qq q q *
RRM2 qq q q ***
ALDH1A1 QQ Q Q * non-small cell bronchopulmonary
cancer; liver cancer; T-cell leukemia
PMAIP1 qq q q ** *
FABP4 QQ Q Q * Bladder cancer;
COL11A1 qq q q adenomas;
TTK qq q q
CENPF qq q q *
‘‘q’’ indicates up-regulated gene expression in the corresponding cancer type while ‘‘Q’’is down-regulation. ‘‘*’’ indicates that a gene has been reported as relevant to
the corresponding cancer type. ‘‘B.’’ for breast cancer; ‘‘C.’’ for colon cancer; ‘‘K.’’ for kidney cancer’’; ‘‘L.’’ for lung cancer’’; ‘‘Pa.’’ for pancreatic cancer’’; ‘‘Pr.’’ for prostate
cancer’’ and ‘‘S.’’ for stomach cancer’’.
doi:10.1371/journal.pone.0013696.t001
Compar Analysis of MultiCancer
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13696enriched in breast cancer; formyltetrahydroformate biosynthesis
in stomach cancer; and NF-kB activation and Csk activation by
cAMP-dependent protein kinase inhibits signaling through T-cell
receptor in kidney cancer. Of particular interest is the finding
that pancreatic cancer has the greatest number of differentially
expressed genes, compared to other cancer types, that are
involved in a complex network consisting of the EGF signaling
pathway, purine and aminosugar metabolism, PKC-catalyzed
phosphorylation of inhibitory phosphoprotein of myosin phos-
phatase, metabotropic glutamate receptor group II pathway, Fc
epsilon receptor I signaling and the BCR and IL 4 signaling
pathways. This suggests a highly active state of the underlying
cells in terms of cell growth, differentiation, invasion and
metastasis, consistent with the known aggressiveness of the
cancer. Seeking the genes and their products that are responsible
for the more aggressive behaviors of pancreatic cancer may
provide new targets for treating the cancer or preventing the
cancer from progression.
A number of pathways specific to a group of cancers have also
been identified, which may suggest common characteristics of the
underlying neoplasms. For example, the glutathione metabolic
pathway is enriched across five cancer types, excluding breast and
prostate cancer; E. coli infection-related pathways are activated in
kidney, lung, pancreatic and stomach cancers but not in other
cancers; the thyrotropin-releasing hormone receptor signaling
pathway is activated in pancreatic and kidney cancer, but not in
the other five cancers; and steroid biosynthesis is activated in
breast, lung and pancreatic cancer but not in the other four
cancers. Cancer-specific pathway activations have been previ-
ously reported. For example, the thyrotropin-releasing hormone
receptor signaling pathway was reported to promote pro-
grammed cell death in pancreatic cancer [58]; steroid biosyn-
thesis in pancreatic cancer was found based on analyses of several
steroidogenic enzymes, such as the cytochrome P-450scc
enzymatic complex (P450scc) that is responsible for the
conversion of cholesterol into pregnenolone.
These diverse findings indicate that comparative analyses of
cancer microarray data can reveal interesting and undetected
relationships across different cancer types/subtypes, thus provid-
ing useful guiding information for further investigation. The
detailed pathway-enrichment information across different cancer
types is summarized in Table S5.
C. Top k-gene markers for multiple cancer types. We
have examined the k-gene combinations among genes that are
differentially expressed in each cancer type to find gene
combinations that are common to multiple cancer types. The
idea is to identify commonalities of gene combinations with
differential expression patterns between cancer and corresponding
control tissue across multiple cancer types, which could provide
useful information about common underlying mechanisms of
carcinogenesis of different cancers.
Table 2 gives the top two 2-gene combinations across at least
three cancer types. CDC2+DPT and CDC2+TOP2A are found to
be good discriminators for five cancer types, namely breast, colon,
lung, prostate and stomach cancers. Similarly, ABCA8+ALD-
H1A1+DPT and ABCA8+AURKA+DPT are good 3-gene
discriminators for four cancer types with higher classification
accuracies than the top 2-gene discriminators, as shown in
Table S6.
As noted, CDC has been reported to play a key role in cell
proliferation and apoptosis [59], and DPT is suggested to have a
possible role in carcinogenesis through its interaction with a known
oncogene, TGFB1. Moreover, some of the top discriminator genes
have been reported to be cancer relevant. For example, ECT2 is
reported to be involved in cancer development, influencing
processes such as the cell cycle, apoptosis and cell division [60];
FABP4 is involved in the activation of the immune response and is
reported to be related to breast cancer [61] and bladder cancer
[62]; and TOP2A is involved in stomach cancer [51]. These
independent observations confirm that the findings herein are
meaningful.
D. Top k-gene markers that are blood secretory. By
combining our blood-secretion prediction capability [6] with the
above top gene discriminators, we have predicted proteins that
may be secreted into circulation, thus providing candidate serum
marker proteins for cancer detection. Table 3 summarizes the top
k-gene discriminators that are predicted to have their proteins
secreted into blood. Some genes involved in these top candidate
discriminators have been previously reported to be cancer related,
e.g. MMP7 [63]. Other predicted blood-secretory marker proteins
such as PAICS, CHRDL1, KLF2, COL10A1 and MYL9 have not
heretofore been reported to be cancer related.
While Table 3 gives a detailed list of all the gene combinations
whose proteins are predicted to be blood secretory, with
Table 2. The top 2-gene markers for multiple cancer types with each numerical value showing the classification accuracy between
a cancer and its corresponding control tissue.
Count Markers Breast Colon Kidney Lung Pancreas Prostate Stomach
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5 CDC2+TOP2A 72.4 94.8 95.3 75.0 100 64.3 _ _ _ 85.2 85.2 79.5 71.2 71.2 87.5 _ _ _ 78.3 85.5 85.2
4 CDC2+DPT 70.7 94.8 96.1 91.7 97.9 64.3 _ _ _ 88.9 92.6 82.1 _ _ _ _ _ _ 66.7 85.5 85.2
CDC2+ECT2 _ _ _ 85.4 97.9 69.0 _ _ _ 83.3 77.8 miss 78.8 86.5 87.5 _ _ _ 75.4 78.3 65.6
ABCA8+AURKA 81.0 96.6 99.2 91.7 100 N.A. _ _ _ 94.4 94.4 92.3 _ _ _ _ _ _ 75.4 92.8 74.1
ABCA8+FABP4 79.3 96.6 91.5 89.6 97.9 85.7 _ _ _ 96.3 98.1 94.9 _ _ _ _ _ _ 79.7 84.1 66.7
DPT+FABP4 79.3 87.9 85.2 95.8 89.6 65.2 _ _ _ 94.4 96.3 94.9 _ _ _ _ _ _ 82.6 75.4 81.5
FABP4+TOP2A 77.6 94.8 93.0 85.4 100 67.6 _ _ _ 96.3 94.4 92.3 _ _ _ _ _ _ 78.3 85.5 88.9
3 CDC2+SULF1 _ _ _ _ _ _ _ _ _ 90.7 88.9 76.9 96.2 90.4 87.5 _ _ _ 95.7 88.4 77.8
Each entry represents the classification accuracy (by percentage) between a cancer set and its corresponding reference set on the training (train) and the testing (test)
datasets, respectively. (N.A. : the platform of the extra test data doesn’t cover the corresponding gene).
doi:10.1371/journal.pone.0013696.t002
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tissues higher than 70%, a few top candidates for these seven
cancer types are highlighted. Three types of cancers are covered
by 22 2-gene combinations, with MMP11+RRM2 and
MMP7+MMP9 representing the top 2-gene markers with at
least 75% classification accuracy. The best 4-gene combination,
MMP7+MMP9+MMP11+RRM2, gives at least 86% classifica-
tion accuracy for lung, pancreatic and stomach cancers, and all of
these four genes are up-regulated by at least 2-fold in the cancer
tissues, suggesting the potential of this combination as a good
blood marker for these cancer types. CCL18+TGFBI represents a
good discriminator for kidney, pancreatic and stomach cancer,
which are up-regulated by at least 2-fold in cancer tissues.
Similarly, CN2+THBS2 are both up-regulated by 2-fold in
kidney, lung and pancreatic cancer. MMP11+RRM2 are up-
regulated in lung cancer, pancreatic cancer and stomach cancer
tissues, and hence may also make a good marker for these three
cancer types.
Concluding Remarks
A computational protocol for predicting gene markers in cancer
tissues and protein markers in sera was developed for simultaneous
analyses of multiple cancer types. In addition to individual gene
markers, we have focused on gene combinations that can be used
to distinguish multiple cancer types from their corresponding
control tissues. The pathway enrichment analysis among the
differentially expressed genes across multiple cancer types, as well
as those specific to individual cancer types, has identified a number
of abnormally activated or deactivated pathways across multiple
cancers and for specific cancers. The information provided on
individual genes and pathways, along with potential serum
biomarkers, should provide highly useful information for elucidat-
ing pathways in cancer, as well as expediting the search for
potential serum biomarkers of specific cancers.
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3 GREM1+MMP7 _ _ _ _ _ _ _ _ _ 88.9 79.6 64.1 92.3 73.1 87.5 _ _ _ 89.9 75.4 63.0
3 MMP7+MMP9 _ _ _ _ _ _ _ _ _ 75.9 79.6 87.2 96.2 78.9 87.5 _ _ _ 77.9 76.8 70.4
3 MMP11+MMP7+MMP9+RRM2 _ _ _ _ _ _ _ _ _ 85.2 96.3 87.2 96.2 88.5 87.5 _ _ _ 88.1 88.4 84.4
3 CCL18+TGFBI _ _ _ _ _ _ 74.5 80.9 80.0 ___8 2 . 7 8 2 . 7 87.5 _ _ _ 71.0 75.4 77.8
3 DPT+MMP7 _ _ _ 97.9 89.6 76.2 _ _ _ 85.2 88.9 87.2 _ _ _ _ _ _ 84.2 81.2 74.1
3 FAM107A+KLF4 _ _ _ 87.5 100 miss _ _ _ 94.4 92.6 94.9 _ _ _ _ _ _ 91.3 92.8 70.4
3 FAM107A+KLF4+MMP7+PAICS _ _ _ 100 100 _ _ _ 94.4 94.4 94.9 _ _ _ _ _ _ 91.3 91.3 84.4
3 INHBA+RRM2 74.1 100 98.4 _ _ _ _ _ _ ___9 4 . 2 8 8 . 5 87.5 _ _ _ 78.3 81.2 74.1
3 GPX3+RRM2 81.0 96.6 96.1 _ _ _ _ _ _ 88.9 94.4 94.9 _ _ _ _ _ _ 85.5 81.2 77.8
3 COL11A1+DPT 72.4 96.6 96.9 97.9 89.6 57.1 _ _ _ 92.6 94.4 87.2 _ _ _ _ _ _ _ _ _
3 MMP11+RRM2 _ _ _ _ _ _ _ _ _ 88.9 90.7 69.2 86.5 88.5 87.5 _ _ _ 75.0 82.6 63.0
Each numerical value represents the classification accuracy (by percentage) between cancer tissues and their corresponding reference tissues.
doi:10.1371/journal.pone.0013696.t003
Compar Analysis of MultiCancer
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13696References
1. WHO (2006) Data and statistics. World Health Organization.
2. Ries LAG MD, Krapcho M (2008) SEER Cancer Statistics Review, 1975–2005
National Cancer Institute.
3. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, et al. (1995)
Evaluation of percentage of free serum prostate-specific antigen to improve
specificity of prostate cancer screening. JAMA 274: 1214–1220.
4. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, et al. (2001)
Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826.
5. Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, et al. (2002) Gene
expression in epithelial ovarian carcinoma. Oncogene 21: 6289–6298.
6. Cui J, Liu Q, Puett D, Xu Y (2008) Computational prediction of human proteins
that can be secreted into the bloodstream. Bioinformatics 24: 2370–2375.
7. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) Large-
scale meta-analysis of cancer microarray data identifies common transcriptional
profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A
101: 9309–9314.
8. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI
gene expression and hybridization array data repository. Nucleic Acids Res 30:
207–210.
9. Lin C-CCaC-J (2001) LIBSVM : a library for support vector machines.Software
available at http://www.csie.ntu.edu.tw/,cjlin/libsvm.
10. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
4: P3.
11. Pau Ni IB, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, et al. (2010)
Gene expression patterns distinguish breast carcinomas from normal breast
tissues: The Malaysian context. Pathol Res Pract.
12. Pedraza V, Gomez-Capilla JA, Escaramis G, Gomez C, Torne P, et al. (2010)
Gene expression signatures in breast cancer distinguish phenotype character-
istics, histologic subtypes, and tumor invasiveness. Cancer 116: 486–496.
13. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, et al. (2003)
Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res
9: 5699–5704.
14. Parr C, Watkins G, Mansel RE, Jiang WG (2004) The hepatocyte growth factor
regulatory factors in human breast cancer. Clin Cancer Res 10: 202–211.
15. Sloan EK, Stanley KL, Anderson RL (2004) Caveolin-1 inhibits breast cancer
growth and metastasis. Oncogene 23: 7893–7897.
16. Jiang WG, Douglas-Jones A, Mansel RE (2003) Expression of peroxisome-
proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-
activator, PGC-1, in human breast cancer correlates with clinical outcomes.
Int J Cancer 106: 752–757.
17. Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, et al. (2003) Angiopoietin-
like 4 is a proangiogenic factor produced during ischemia and in conventional
renal cell carcinoma. Am J Pathol 162: 1521–1528.
18. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, et al. (2007) Whole genome
analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer
121: 2005–2012.
19. Jiang X, Tan J, Li J, Kivimae S, Yang X, et al. (2008) DACT3 is an epigenetic
regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic
target of histone modifications. Cancer Cell 13: 529–541.
20. Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, et al. (2003)
Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1
and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic
colorectal cancers. Int J Cancer 107: 183–188.
21. Wang WS, Chen PM, Wang HS, Liang WY, Su Y (2006) Matrix
metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a
poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 27:
1113–1120.
22. Jones J, Otu H, Spentzos D, Kolia S, Inan M, et al. (2005) Gene signatures of
progression and metastasis in renal cell cancer. Clin Cancer Res 11: 5730–5739.
23. Someya S, Yamasoba T, Kujoth GC, Pugh TD, Weindruch R, et al. (2008) The
role of mtDNA mutations in the pathogenesis of age-related hearing loss in mice
carrying a mutator DNA polymerase gamma. Neurobiol Aging 29: 1080–1092.
24. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, et al. (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone
modifying genes. Nature 463: 360–363.
25. Hart TC, Gorry MC, Hart PS, Woodard AS, Shihabi Z, et al. (2002) Mutations
of the UMOD gene are responsible for medullary cystic kidney disease 2 and
familial juvenile hyperuricaemic nephropathy. J Med Genet 39: 882–892.
26. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, et al. (2008) Gene
expression signature of cigarette smoking and its role in lung adenocarcinoma
development and survival. PLoS One 3: e1651.
27. Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, et al. (2007) Selection of DDX5
as a novel internal control for Q-RT-PCR from microarray data using a block
bootstrap re-sampling scheme. BMC Genomics 8: 140.
28. Park SS, Kim JE, Kim YA, Kim YC, Kim SW (2005) Caveolin-1 is down-
regulated and inversely correlated with HER2 and EGFR expression status in
invasive ductal carcinoma of the breast. Histopathology 47: 625–630.
29. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, et al. (2002) Up-regulated
caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by
inducing filopodia formation. Am J Pathol 161: 1647–1656.
30. Bridges JP, Wert SE, Nogee LM, Weaver TE (2003) Expression of a human
surfactant protein C mutation associated with interstitial lung disease disrupts
lung development in transgenic mice. J Biol Chem 278: 52739–52746.
31. Kholodnyuk ID, Kozireva S, Kost-Alimova M, Kashuba V, Klein G, et al.
(2006) Down regulation of 3p genes, LTF, SLC38A3 and DRR1, upon growth
of human chromosome 3-mouse fibrosarcoma hybrids in severe combined
immunodeficiency mice. Int J Cancer 119: 99–107.
32. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I (2008) Combined gene
expression analysis of whole-tissue and microdissected pancreatic ductal
adenocarcinoma identifies genes specifically overexpressed in tumor epithelia.
Hepatogastroenterology 55: 2016–2027.
33. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, et al. (2009) FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell
16: 259–266.
34. Tang L, Dai DL, Su M, Martinka M, Li G, et al. (2006) Aberrant expression of
collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer
Res 12: 3716–3722.
35. Groundwater P, Beck SA, Barton C, Adamson C, Ferrier IN, et al. (1990)
Alteration of serum and urinary lipolytic activity with weight loss in cachectic
cancer patients. Br J Cancer 62: 816–821.
36. Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, et al. (2007)
Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory
responses. Cell Signal 19: 748–760.
37. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, et al. (2005)
Differences in gene expression in prostate cancer, normal appearing prostate
tissue adjacent to cancer and prostate tissue from cancer free organ donors.
BMC Cancer 5: 45.
38. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. (2004) Gene
expression profiling identifies clinically relevant subtypes of prostate cancer. Proc
Natl Acad Sci U S A 101: 811–816.
39. Varadhachary A, Wolf JS, Petrak K, O’Malley BW, Jr., Spadaro M, et al. (2004)
Oral lactoferrin inhibits growth of established tumors and potentiates
conventional chemotherapy. Int J Cancer 111: 398–403.
40. Soulitzis N, Karyotis I, Delakas D, Spandidos DA (2006) Expression analysis of
peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer
and benign prostatic hyperplasia. Int J Oncol 29: 305–314.
41. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, et al. (2002) Insulin-like
growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-
stage prostate cancer. J Natl Cancer Inst 94: 1099–1106.
42. Kane R, Godson C, O’Brien C (2008) Chordin-like 1, a bone morphogenetic
protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and
plays a role in regulating angiogenesis. Mol Vis 14: 1138–1148.
43. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, et al. (2003) Variation in gene
expression patterns in human gastric cancers. Mol Biol Cell 14: 3208–3215.
44. D’Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, et al. (2009) Genome-
wide expression profile of sporadic gastric cancers with microsatellite instability.
Eur J Cancer 45: 461–469.
45. Peng Z (2010) Expression data from gastric cancer (GSE19826). In: Hospital
SJTUAFPs, editor. Shanghai.
46. Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H, et al. (2002) Smad4/
DPC4-dependent regulation of biglycan gene expression by transforming growth
factor-beta in pancreatic tumor cells. J Biol Chem 277: 36118–36128.
47. Ning PF, Sun LP, Liu HJ, Yuan Y (2004) [Expression of pepsinogen C in gastric
cancer and its precursor]. Zhonghua Yi Xue Za Zhi 84: 818–821.
48. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F (2003)
Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic
gastritis in European dyspeptics. Br J Cancer 88: 1239–1247.
49. www.cancer.org (2006) Cancer Facts & Figures. In: Society AC, ed.
50. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
51. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, et al. (2004) Coamplified
and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 109:
548–553.
52. Koren R, Rath-Wolfson L, Ram E, Itzhac OB, Schachter B, et al. (2004)
Prognostic value of Topoisomerase II in female breast cancer. Oncol Rep 12:
915–919.
53. Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, et al. (2006) Altered
expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and
stromal cells after platinum-based chemotherapy. Neoplasia 8: 38–45.
54. Aota Y, Sumi M, Iguchi T, Okabe S, Gotoh A, et al. (2004) Type I CD36
deficiency in hematologic disorder. Haematologica 89: EIM17.
55. Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, et al. (2008) ALOX5
variants associated with susceptibility to human pulmonary tuberculosis. Hum
Mol Genet 17: 1052–1060.
56. Piovan E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, et al. (2005) Chemokine
receptor expression in EBV-associated lymphoproliferation in hu/SCID mice:
implications for CXCL12/CXCR4 axis in lymphoma generation. Blood 105:
931–939.
57. Lee HY, Kim MK, Park KS, Bae YH, Yun J, et al. (2005) Serum amyloid A
stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor
like-1-mediated signaling in human monocytic cells. Biochem Biophys Res
Commun 330: 989–998.
Compar Analysis of MultiCancer
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e1369658. Mulla CM, Geras-Raaka E, Raaka BM, Gershengorn MC (2009) High levels of
thyrotropin-releasing hormone receptors activate programmed cell death in
human pancreatic precursors. Pancreas 38: 197–202.
59. Ababneh M, Gotz C, Montenarh M (2001) Downregulation of the cdc2/cyclin
B protein kinase activity by binding of p53 to p34(cdc2). Biochem Biophys Res
Commun 283: 507–512.
60. Eguchi T, Takaki T, Itadani H, Kotani H (2007) RB silencing compromises the
DNA damage-induced G2/M checkpoint and causes deregulated expression of
the ECT2 oncogene. Oncogene 26: 509–520.
61. Li H, Lu Q, Dong LH, Xue H, Zhou HY, et al. (2007) [Expression of fatty acid
binding protein in human breast cancer tissues]. Xi Bao Yu Fen Zi Mian Yi Xue
Za Zhi 23: 312–316.
62. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE (2005) Loss of expression
of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with
progression of human urothelial carcinomas. Mol Cell Proteomics 4: 570–581.
63. Zhang J, Jin X, Fang S, Wang R, Li Y, et al. (2005) The functional
polymorphism in the matrix metalloproteinase-7 promoter increases suscepti-
bility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma
and non-small cell lung carcinoma. Carcinogenesis 26: 1748–1753.
Compar Analysis of MultiCancer
PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13696